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Abstract
Objective Compare vitamin D levels in opioid dependence
and control population and adjust for relevant confounding
effects. Nuclear hormone receptors (including the vitamin
D receptor) have been shown to be key transducers and
regulators of intracellular metabolism and comprise an
important site of pathophysiological immune and metabolic
dysregulation potentially contributing towards pro-ageing
changes observed in opioid-dependent patients (ODPs).
Design Longitudinal prospective comparing ODPs with
general medical controls (GMCs).
Setting Primary care.
Participants Prospective review comparing 1168 ODP
(72.5% men) and 415 GMC (51.6% men, p<0.0001). Mean
ages were 33.92±0.31 (mean±SEM) and 41.22±1.32 years,
respectively (p<0.0001). Opioid use in the ODP has been
previously reported and shown to be typical.
Interventions Nil. Observational study only.
Primary and secondary outcomes Serum vitamin D
levels and relevant biochemical parameters.
Results Vitamin D levels were higher in the ODP
(70.35±1.16 and 57.06±1.81 nmol/L, p<0.0001). The
difference in ages between the two groups was handled in an
age-matched case–control subanalysis and also by multiple
regression. Sexes were analysed separately. The age:status
(or age:time:status) was significant in case–control, crosssectional and longitudinal analyses in both sexes (p<0.05).
Modelled vitamin D was 62.71 vs 57.81 nmol/L in the two
groups. Time-dependent mixed-effects models quadratic in
age outperformed linear-only models (p=0.0377). ODP vitamin
D was shown to vary with age and to correlate with alanine
aminotransferase establishing it as a biomarker of age in this
group. Hepatitis C seronegativity was significant in regression
models (from p=0.0015).
Conclusion Vitamin D was higher in ODP in both sexes
in bivariate, cross-sectional, case–control and longitudinal
analyses and was robust to the inclusion of metabolic and
immune biomarkers. That Hepatitis C seronegativity was
significant suggests opioid dependence has an effect beyond
simply that of its associated hepatitides. This finding may
relate to the accelerated ageing process previously described
in opioid dependence.

Introduction
Vitamin D and its nuclear steroid receptor have
been implicated in a wide range of physiological

Strengths and limitations of this study
►► Strengths of this study included its large sample

size, prospective and longitudinal design and realworld sampling in primary care.
►► The involvement of nuclear hormone receptor
signalling in coordinating metabolic and immune
systems provides an important insight into a major
network of pathways which may contribute to the
altered pathophysiological experience of drug
dependent cohorts.
►► Study weaknesses included the unavailability of
socioeconomic or occupational data which may
impact on the amount of sun exposure derived from
differing lifestyles and vocational exposure.
►► Vitamin D receptor assays and assays for the various
vitamin D metabolites were also not available to this
study.

and developmental functions including skeletal, immunological, muscle strength and
tendon function, metabolic syndrome and
obesity, cardiovascular disease, endocrine
disorders including diabetes, neuropsychiatric
disorders, oncogenesis of several cancers, development and many cellular function.1–4 Many of
these age-related morbidities are increasingly
associated with opiate use.5–9 However, a literature search of the PubMed, Scopus and Ebsco
Host online databases revealed no reports of
the impact of opiate dependency on vitamin
levels, other than a single report of its association with the adequacy of pain control in a
cohort of patients with chronic pain.10
This whole area has recently been shown
to be of enormous clinical importance by
the increasing significance of vitamin D in
multiple sclerosis11–17although this relationship remains controversial.18–20
The subject is of importance for several
reasons. There are several reports of elevated
rates of osteoporosis/osteopaenia in opioid-dependent cohorts.5 8 21 Higher levels of calcium,
phosphate and their solubility product have
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Methods
Patient selection
All ODPs and general medical controls (GMCs) attended
a single metropolitan outpatient clinic, with data collected
by retrospective review of patient records. All patients in
whom a vitamin D assay was requested were included in
the analysis. There was no selection of patients based on
age. Hepatitis C serology was routinely only performed on
opiate-dependent patients, and was used as a surrogate
marker for retrospectively identifying opiate-dependent
patients. Hence, patients were considered to be opioid
dependent where the hepatitis C test was performed or
the hepatitis C virus (HCV) RNA PCR test was positive. In a
few cases, data were manually curated to correct anomalies.
2

The two study groups are thus described as being ODPs and
GMCs. Other blood tests were taken as clinically required in
the process of routine medical care.
Pathology analysis
As a high rate of abnormally low vitamin D levels was
quickly noted in all our patients, this test was ordered
routinely on all patients who required clinical pathology to
be performed. All clinical pathology was undertaken by the
Queensland Medical Laboratory (QML) which is accredited by the National Association of Testing Authorities
Australia to the Australian Laboratory standard AS-15189.
QML is also accredited to the international standard ISO
9001 the international laboratory clinical standard. The
form of vitamin D measured was 25-hydroxycholecalciferol.
The calcium–phosphate solubility product was defined as is
usual in chemistry as the product of the cube of the serum
calcium concentration and the square of the phosphate
concentration as previously described.22
Statistics
The pathology results were downloaded as an Excel
spreadsheet from QML for the period 1995–2017. Data
are listed as mean±SEM. Categorical data were compared
in EpiInfo V.7.2.0.1 from Centres for Disease control
in Atlanta, Georgia, USA using the adjusted MantelHaenszel statistic. Bivariate statistics were compared by
categories in Statistica V.7.1 from Statsoft, Oklahoma,
USA. Student’s test for t with separate variances was
utilised as indicated by the Levene test. This is reported
in table 1 as fractional df.
‘R’ V.3.3.2 was downloaded from the University of
Melbourne Central ‘R’ Archive Network mirror. Multiple
regression was performed in ‘R’ and graphs were drawn in
R using the ggplot2 package. Loess (localised polynomial
curves) were drawn at a span=0.95. Multiple regression
model reduction was performed by the classical method
with deletion of the least significant term until only significant terms remained. Deidentified confidential data may
be made available to interested readers and researchers on
written request to the authors. Continuous data of such as
vitamin D, alanine aminotransferase (ALT), serum globulins and C-reactive protein were log transformed in multiple
regression analyses as indicated by the results of the Shapiro
test. Chronological age was not log transformed in the interests of improving model fit. Linear and polynomial models
were compared using analysis of variance (ANOVA) tests in
R. Missing data were case-wise deleted. All t-tests were two
tailed. p Value <0.05 was considered significant.
Ethics
Strict patient confidentiality was maintained throughout
the data analysis phase. The study was conducted in
accord with the Declaration of Helsinki.
Results
In the period 1995–2017, 1583 patients had a vitamin
D study performed on 2099 occasions. Of these, 1168
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806
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previously been reported in opioid-dependent patients
(ODPs).22
Increased vascular stiffness has also been reported in
both male and female patients.7 23 It may be that higher
levels of vascular stiffness—and vascular age—are causally
associated with disruptions of vitamin D physiology. Moreover, a number of tumours have also been noted to be
seen at higher incidence in ODPs24–26 which may relate to
either altered nutritional, metabolic or immune factors.
Chronic muscle and joint pain is also a common feature
of opioid withdrawal which many dependent patients
experience on a daily basis and is known not to respond
to non-narcotic analgesics.10 27
The evidence from numerous sources is remarkably
consistent and increasingly strong for a pattern of accelerated ageing in opioid dependence.7 23 Subcellular
oxidative damage particularly arising from immune
mechanisms is increasingly emerging as a principal determinant of ageing processes.28 29 As an important modifier
of immune dysregulation,30–34 it is therefore plausible that
vitamin D physiology may impinge on the ageing process
in a clinically significant manner and may be of particular
relevance to the immune dysregulation well described in
opioid dependence35–39 and the accompanying syndrome
of accelerated ageing.
Moreover, complex interactions are increasingly being
documented between nutritional, immune, gastrointestinal
and metabolic biomarkers40–42 making multiway interactions
both analytically feasible and physiologically meaningful.43
The following study was therefore conducted prospectively to ascertain (i) the comparative levels of vitamin D in
opiate-dependent and non-dependent clinical populations
including sex differentials and comparative levels of hypovitaminosis D; (ii) to document the relationship of chronological age with changes in vitamin D status in dependent and
non-dependent groups and therefore its role as a potential
biomarker of ageing and (iii) to document significant associated changes in metabolic and innate and adaptive immune
function with vitamin D levels. As our clinic sees significant
numbers of both ODPs and non-dependent patients, we are
ideally suited to compare opioid-dependent and non-dependent cohorts.

Open Access

Valid N
Control ODP

Mean (+SEM)
Control

ODP

Statistics
t

df

P value

All patients—initial values
 Age (years)

176

739

41.22 (1.32)

33.92 (0.31)

−5.38

194.71

<0.0001

 Haemoglobin (g/dL)

167

731

142.65 (1.00)

147.23 (0.50)

3.98

896.00

0.0001

9

 Platelets (×10 /L)

166

728

267.72 (4.98)

267.81 (2.65)

0.01

892.00

0.9882

 White cell count (×109/L)

167

731

7.95 (0.59)

8.4 (0.09)

0.75

173.80

0.4515

 Neutrophil absolute (×10 /L)

167

731

4.91 (0.60)

4.97 (0.08)

0.10

171.52

0.9169

 Lymphocyte absolute (×109/L)

167

731

2.82 (0.60)

2.54 (0.03)

−0.47

167.06

0.6401

 Monocytes absolute (×10 /L)

167

731

1.18 (0.60)

0.65 (0.01)

−0.88

166.07

0.3813

 ESR (mm/hour)

167

720

12.08 (1.20)

10.88 (0.37)

−0.95

198.43

0.3408

 High-sensitivity CRP (mg/dL)

166

739

6.21 (1.75)

6.93 (0.50)

0.54

903.00

0.5921

 Total bilirubin (mmol/L)

171

739

10.85 (0.66)

8.1 (0.18)

−3.99

196.36

0.0001

 Alkaline phosphatase (IU/L)

171

739

80.87 (3.81)

81.33 (1.05)

0.12

196.52

0.9070

 ALT (IU/L)

171

739

29.24 (1.63)

80.59 (9.11)

5.55

782.28

<0.0001

 AST (IU/L)

171

739

28.26 (1.03)

60.21 (8.40)

3.78

759.46

0.0002

 LDH (IU/L)

171

738

172.84 (2.91)

199.87 (6.00)

2.15

907.00

0.0315

 GGT (IU/L)

171

739

33.27 (2.61)

51.25 (2.32)

5.14

477.24

<0.0001

 Total protein (g/L)

171

739

73.28 (0.39)

75.03 (0.19)

3.96

908.00

0.0001

 Albumin (g/L)

171

739

43.47 (0.40)

42.76 (0.12)

−2.20

908.00

0.0278

 Globulin (g/L)

171

739

30.4 (0.49)

32.26 (0.15)

4.75

908.00

<0.0001

 Cholesterol (mmol/L)

171

739

5.64 (0.57)

4.55 (0.04)

−1.90

171.53

0.0586

 Triglyceride (mmol/L)

171

739

2.15 (0.61)

1.45 (0.04)

−1.15

171.29

0.2500

 LDL (mmol/L)

84

717

14.55 (3.49)

2.38 (0.03)

−3.49

83.01

0.0008

 HDL (mmol/L)

84

717

13.25 (3.54)

1.24 (0.02)

−3.39

83.00

0.0011

 Vitamin D (nmol/L)

176

739

57.06 (1.81)

70.35 (1.16)

6.19

334.41

<0.0001

 Age (years)

331

331

40.08 (0.62)

40.34 (0.64)

5.5716

330.00

<0.0001

 Vitamin D (nmol/L)

331

331

59.73 (1.66)

64.24 (1.52)

2.0044

330.00

0.0458

 ALT (IU/L)

303

331

32.59 (1.47)

61.74 (7.20)

6.8776

593.15

<0.0001

 AST (IU/L)

303

331

28.41 (0.83)

49.22 (3.17)

8.9718

547.13

<0.0001

 Globulin (g/L)
 High-sensitivity CRP (mg/dL)

303
272

331
329

30.31 (0.21)
5.26 (0.73)

33.18 (0.25)
6.34 (0.76)

8.7564
2.4738

629.68
578.35

<0.0001
0.0137

9

9

Case–control series
Paired t-tests

Non-paired t-tests

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation
rate; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density
lipoprotein; ODP, opioid-dependent patient.

patients were treated for opioid dependence and 415
patients were treated for general medical conditions. It
is noteworthy that 98% of this study was sampled prior
to the introduction of universal coverage for hepatitis C
treatment in Australia in March 2016.
Overall, there were 1061 men and 522 women. Out of
1168 ODPs, 847 (72.52%) were men and out of 415 GMCs,
214 (51.57%) were men (Mantel-Haenszel χ2=60.77,
p<0.0001). In the longitudinal sample including repeat
tests, 1031/1437 (71.75%) of opioid-dependent samples
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806

were from men and 350/662 (52.87%) of the general
medical samples were taken from men (Mantel-Haenszel
χ2=71.72, p<0.0001).
Patients were considered to be hepatitis C positive
if either the HCV antibody or their serum PCR study
was positive for hepatitis C RNA. Among the ODPs,
301 were hepatitis C antibody seronegative and 867
were antibody positive. Among the medical controls,
406 were untested, 1 was seronegative and 8 were
positive. Hence, 74.23% of the ODPs were hepatitis
3
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Case–control series
In the case–control study, it was possible to pair 331
GMCs with 331 ODPs by age. The age of the ODPs was
40.07±0.62 years and that of the GMCs was 40.34±0.64
years (Student’s paired t-test t=7.13, df=330, p<0.0001).
The mean difference in ages was 0.26 years. However, the
ages were not significantly different if a non-paired t-test
was used (t=0.29, df=660, p=0.76). In 20 of the 331 pairs
(7.5%) the age difference was >|1|; and in 49/331 pairs
(14.8%) the age difference was greater than an absolute
difference of |0.5|. The comparative age distributions are
4

shown in superimposed histogram and contour plots (see
the online supplementary figure 3).
While the two groups had a similar sex ratio, being
50.76% and 51.36% men, respectively (Mantel-Haenszel
χ2=0.2, p=0.87) they were not sex-matched at the single
pair level (Wilcoxson W=53 464, p=0.82).
Selected bivariate parametric comparison from the
case–control cohort are shown in the lower part of table 1.
The mean vitamin D in these two groups was
64.24±1.52 and 59.73±1.66, respectively (Student’s paired
t-test t=5.57, df=330, p<0.0001). These values are charted
for the initial cross-sectional group in figure 1C.
When the (log) vitamin D status was regressed against
age in a linear regression model in each case the age:
addictive status interaction was significant in all patients,
and in women (top half of table 2). The age: status interaction approached significance in men (p=0.066). In a
linear model quadratic in age, both the addictive status
and the age squared:status interaction were significant
(table 2). The model quadratic in age was superior to the
model linear in age (F=3.422, df=3, p=0.0178).
When the (log) vitamin D level was regressed against
age and time in a mixed-effects model using restricted
maximum likelihood modelling techniques, the addictive
status was significant both in its own right (p=0.0009) and
in interaction with age (p=0.0180), as show in the top of
table 3. In a model quadratic in age, the addictive status
was significant (p=0.0004) and it was also significant in
interactions with age and time (from p=0.0021). The
model quadratic in age was superior to the model linear
in age (log ratio=14.80, df=5, p=0.0112).
Multiple regression in the whole dataset
We then move on to the whole dataset first looking at the
initial cross-sectional values. In these studies, the (log)
vitamin D level is regressed against age and addictive
status. These results are summarised in the lower half of
table 2 which found significant differences by group and
by sex.
The effect size between the two groups can be calculated from this model. When one enters the median age
(35.83 years) for the cross-sectional dataset in the regression model, the modelled levels of vitamin D are 62.71
and 57.81 nmol/L in the ODP and GMC groups, respectively. This represents a 4.90 nmol/L difference or 8.47%
advancement on the level in the control group.
A model quadratic in age was also calculated for the
initial cross-sectional data with results shown in the
lower half of table 2. However, on formal testing, it was
not superior to the strictly linear model (F=1.7085, df=2,
p=0.1815).
When all the data (n=2099) are considered in a
time-dependent mixed-effects model, the results shown
in the middle portion of table 3 are obtained. In these
models, the (log) serum vitamin D levels is regressed
against age, time and drug dependence status with the
case number as the random effect. A similar model was
calculated quadratic in age with results shown at the top
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806
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C seropositive, compared with only 1.93% (8/415)
of the GMCs (Mantel-Haenszel extended χ2 test for
trend=12300.10, p<0.0001).
Table 1 gives the initial bivariate cross-sectional comparative data for selected laboratory parameters. In particular, one notes a significant difference in chronological
age between the opioid-dependent and general medical
groups 33.92±0.31 versus 41.22±1.32 years (mean±SEM,
t=5.38, sep. var. df=194.71, p<0.0001). Several of the liver
tests are higher in the opioid-dependent group. Some of
the lipid parameters are lower likely reflecting a lower
body weight as has previously been reported in patients
from this cohort.7 Drug use data in this cohort have been
previously reported.7 23 44–46
One notes that the vitamin D level is much higher in
the ODPs 70.35±1.16 vs 57.06±1.81 mmol/L than in the
GMCs (t=6.19, sep. var. df=334.41, p<0.0001). Low levels
of vitamin D (<50 nmol/L) were less frequent in the
ODP group than in the GMC group (27.48% vs 45.3%,
OR=0.46, 95% CI 0.36 to 0.58, Mantel-Haenszel χ2=44.53,
df=1, p<0.0001).
Vitamin D levels in the cohort is charted by age in
figure 1A,B and by time in figure 2 (see the online supplementary figure 1) provides a similar plot to figure 1A but
is drawn with loess curves which closely approximate
straight lines, confirming the utility of linear modelling
in this analysis. The effect of time is shown in the online
supplementary figure 2, where it is shown that linear
modelling approximates the effect of passing time less
well.
ALT is a well-recognised clinical biomarker of metabolic
ageing.39 47 (Log) vitamin D level was shown to correlate
with the (log) serum ALT in opioid dependence both in
the cross-sectional initial group (Spearman R=0.0951,
t=3.26, df=1166, p=0.0011) and the longitudinal group
(Spearman R=0.0984, t=3.75, df=1435, p=0.0002). This
correlation was not significant among GMCs. Another
biomarker, serum globulin, was not significantly
correlated with vitamin D in any group.
These figures show a clear age effect. Hence, the very
different ages in our two major groups may have had an
effect on the parameter of interest. This age disparity
was addressed in two ways. First by using a case–control
comparison group from within the larger group, and
second by using multiple regression and correcting for
the effects of chronological age.

Open Access

of table 3. It was found to be superior to the linear model
(log ratio=8.445, df=3, p=0.0377).
One notes that when sex is included in the model the
age:time:status interaction is significant. Sex is included
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806

in one term in the final model. The age:status interaction is significant when all patients are considered
together and in men and women separately. In women,
this appears as an interaction between time, age and
5
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Figure 1 Vitamin D and log vitamin D by chronological age, opioid dependency and sex in (A) whole cohort, (B) initial values
and in (C) case–control study.
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Serum vitamin D status by time in (A) first 3 years and (B) across whole period.

status. These results imply that vitamin D is a biomarker
of age.
No correlation between vitamin D status and the
calcium–phosphate solubility product in the whole
sample was demonstrated (Pearson R=0.019, t=0.86,
df=2044, p=0.39).
In previous studies, the serum globulins and ALT have
been the most discriminative clinical pathological variables and these parameters also show marked age-dependent effects.39 48 49 Therefore, these results were included
in time-dependent mixed-effects linear regression models
for all patients and for each sex separately. The outcomes
of these analyses are shown in the lower part of table 3. In
each case, the addictive status is significant.
6

The demonstration that ALT and serum globulins
are close correlates of the elevated vitamin D in opioid
dependence raises the question of the possible relationship of liver disease with this observation. Preliminary
analyses showed that the hepatitis B serostatus was less
discriminatory than hepatitis C serostatus, so the analysis in this section focused on hepatitis C. Note that in
this study, technical factors may blur the definitions of
the opioid dependence status and hepatitis C serostatus
as in the present work, as elsewhere,37–39 49–53 the opioid
dependence status was defined in terms of the hepatitis
serological results.
The results are as shown in figure 3 where the majority
of the effect seems to reside with the hepatitis C-positive
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806
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Figure 2
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Parameter estimates
β-Estimate

SE

Model

t Value

P value

F

Adj. R

2

df

P value

Case–control series
Linear model
All patients
 Age:status addicted

−0.4778

0.1768

−2.702

0.0073

 Status addicted

24.8561

11.0893

2.241

0.0258

6.83

0.0613

3, 265

0.0002

  Status addicted

0.2634

0.0609

4.326

0.0000

2

0.0961

6.7000

5, 263

<0.0001

3.1664

1.0301

3.074

0.0023

2

−2.5316

0.8370

−3.025

0.0027

−0.4232

0.2288

−1.85

0.0668

2.6300

0.02524

2, 124

0.0760

−0.0145

0.0038

−3.788

0.0002

9.6000

0.0664

2, 139

0.0001

0.0071

0.0021

3.331

0.0011

0.4547

0.0852

5.337

<0.0001

−0.0071

0.0016

−4.505

<0.0001

0.2112

0.0321

6.572

<0.0001

−4.1647

1.3631

−3.055

0.5628

0.1195

4.709

<0.0001

−0.0083

0.0019

−4.423

<0.0001

0.1723

0.0400

4.308

<0.0001

 Quadratic model
  (Age) :status addicted
  (Age)
 Men
  Age:status control
 Women
  Age
  Age:status addicted
All patients
Linear model
 Status addicted
 Age:status addicted

0.0585

33.75

3, 1579

<0.0001

0.0593

20.95

5, 1577

<0.0001

0.0599

23.52

31, 057

<0.0001

0.03261

18.56

1, 520

<0.0001

 Quadratic model
  Status addicted
  Age:status addicted

0.00229

 Men
  Status addicted
  Age:status addicted
 Women
  Status addicted

group. This is formally confirmed by regression analysis
results shown in the first segment of table 4. However, as
shown in the lower panels of figure 3, some of the data for
the hepatitis C serostatus is apparently non-linear. Therefore, low-order models polynomial in age were compared
with the linear model. The results of the model quadratic
in age are shown in the lower section of table 4. Formal
model comparison using ANOVA testing confirmed that
the model quadratic in age was superior to the linear
model (log ratio 19.83 on 5 df, p=0.0013). A similar model
quadratic in time failed to converge. A model quadratic
in both age and time also failed to converge.
A complete mixed-effects model of the multiple regression correlates of serum vitamin D was therefore constructed
including age, time, ALT, globulins and hepatitis serostatus
were included in the model and reduced by the classical
model reduction procedure. Because of the superiority
of the quadratic model in the more streamlined analysis
described in the preceding paragraph, this model included
a term quadratic in age. Sex was not included in the final
model as it was not significant in the applicable preceding
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806

model as noted above. The final model derived by this
procedure is shown in the third section of table 4. In this
final model, the only parameter which was independently
correlated with serum vitamin D was the serum ALT level.
No quadratic term in age was significant in the final model.
Interestingly, notwithstanding the inclusion of both globulins and ALT, the hepatitis C serostatus was significantly
correlative and was included in 8 of the 12 terms in the
final model. Terms including hepatitis C seropositivity were
significant from p<0.0001 and terms including hepatitis C
seronegativity were significant from p=0.0475.
This final model was shown to be superior to the preceding
quadratic model without biochemical parameters included
by ANOVA testing (log ratio=19.53 on df=9, p=0.0021).
Discussion
The main results of this prospective longitudinal study
were that the serum vitamin D levels in ODPs were
higher than that in the general medical controls both
as a mean level overall and in multiple regression
7
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Parameter
Variable

Value

SE

df

Model
t Value

p Value

AIC

BIC

logLik

1046.232

1077.646

−516.1161

1077.582

1131.343

−526.7911

2737.466

2776.991

−1361.733

2745.271

2796.080

−1363.636

1809.922

1851.731

−896.9608

984.101

1011.518

−486.0503

2641.788

2703.304

−1309.894

1862.039

1924.291

−919.0196

Case–control series
Linear model
 Status addicted
 Age:status addicted

0.3814

0.1121

118

3.4025

0.0009

−0.0062

0.0026

118

−2.3991

0.0180

 Days

0.0001

0.0000

118

2.3023

0.0231

 Age:days

0.0000

0.0000

118

−2.2675

0.0252

0.1798

0.0497

113

3.6176

0.0004

Quadratic model
 Status addicted
2

 (Age) :days:status addicted
 Age:days:status addicted
 Days:status addicted

−0.0017

0.0005

113

−3.1549

0.0021

0.0026

0.0009

113

2.8283

0.0055

−0.0001

0.0000

113

−2.7344

0.0073

 Age:status addicted

−2.3528

0.8716

113

−2.6995

0.0080

 Age:days

−0.0009

0.0004

113

−2.5102

0.0135

0.0000

0.0000

113

2.1706

0.0321

 Days
All patients

0.4253

0.0588

514

7.2353

0.0000

 Age:status addicted

 Status addicted

−0.0072

0.0015

514

−4.8060

0.0000

 Days:status addicted

−0.0003

0.0001

514

−4.7578

0.0000

0.0000

0.0000

514

3.7269

0.0002

 Age:days
All patients including sex
 Status addicted
 Age:status addicted

0.3496

0.0637

512

5.4913

0.0000

−0.0072

0.0015

512

−4.7819

0.0000

 Age:days:status addicted

0.0000

0.0000

512

−4.4102

0.0000

 Sex man:status addicted

0.1127

0.0289

512

3.9009

0.0001

 Age:days

0.0000

0.0000

512

3.6454

0.0003

−0.0084

0.0018

317

−4.6726

0.0000

Men
 Age:status addicted
 Status addicted

0.4560

0.1124

317

4.0554

0.0001

 Days:status control

0.0002

0.0001

317

2.7606

0.0061

−0.0001

0.0001

317

−2.7125

0.0070

0.0000

0.0000

193

−3.3598

0.0009

 Days:status addicted
Women
 Age:days:status addicted
 Status addicted

0.1027

0.0381

193

2.6984

0.0076

 Age:days

0.0000

0.0000

193

2.5055

0.0131

0.1022

0.0191

442

5.3506

0.0000

All patients including biochemistry
 ALT:status addicted

−0.0018

0.0004

442

−4.4320

0.0000

 Age:days:ALT:globulin:status addicted

 Age:ALT:status addicted

0.0000

0.0000

442

−3.3350

0.0009

 Age:days:ALT:globulin:Status control

0.0000

0.0000

442

2.8871

0.0041

−0.0107

0.0050

442

−2.1345

0.0334

 ALT:globulin:status control
Males with biochemistry

0.1022

0.0209

281

4.8779

0.0000

 Age:ALT:status addicted

 ALT:status addicted

−0.0020

0.0005

281

−4.3398

0.0000

 Days:ALT:status addicted

−0.0001

0.0000

281

−3.9903

0.0001

 Days:ALT

0.0001

0.0000

281

2.8297

0.0050

 Age:days:ALT:globulin

0.0000

0.0000

281

−2.3787

0.0180

Continued
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Parameter
Variable

Value

SE

df

Model
t Value

p Value

 Days:ALT:globulin

0.0003

0.0001

281

2.3190

0.0211

 Age:days:globulin

0.0000

0.0000

281

2.3006

0.0221

−0.0010

0.0005

281

−2.2099

0.0279

 Days:globulin

AIC

BIC

logLik

1037.669

−476.754

Females with biochemistry
 Globulin:status addicted
 Age:globulin:status addicted
 Age:dd:ALT:globulin:status addicted
 ALT:globulin
 Age:ALT:globulin:status addicted

0.2158

0.0669

150

3.2246

0.0015

−0.0076

0.0024

150

−3.1375

0.0021

0.0000

0.0000

150

−2.9772

0.0034

−0.0394

0.0139

150

−2.8385

0.0052

0.0016

0.0006

150

2.8339

0.0052

 Age:days:ALT

0.0000

0.0000

150

2.5096

0.0132

 Age:days

0.0000

0.0000

150

−2.3426

0.0205

979.508

AIC, Akaike Information Criterion; ALT, alanine aminotransferase; BIC, Bayesian Information Crieterion; DD, days; logLik, Log Likelihood ratio.

models by dependency status and/or by the age: dependency status interaction in both sexes. The advance in
the modelled vitamin D level with age was shown to be
8.47%. The vitamin D level did not change with age in
the control group, but it did fall significantly with age
in the opioid-dependent group, making it a negative
biomarker of ageing in this group. It was also shown to
be significantly correlated with ALT, a well-recognised
biomarker of age. Many differences exist between the
ODPs and GMCs, however the effect appeared to be
robust to adjustment for many of these features. While
hepatitis C was an important predictor of the vitamin D
level, it did not account for the effect of opiate dependency, as it was also observed in the HCV seronegative
group. On multivariate analysis, vitamin D level was
found to be significantly associated with interactive
terms including ALT and measures of immune function
such as serum globulins. The reasons for the higher
levels of vitamin D in the opioid-dependent group are
not clear and the present work is not designed as a
mechanistic exploration. Unpublished data from this
cohort show that the socioeconomic profile of the ODP
and GMC groups is very different, with many more
tradesmen and welfare-dependents in the ODP group
which might be expected to have higher and lower
than normal sun exposure, respectively. The primary
analyte in this study was 25-hydroxyvitamin D. As the
25-hydroxylation reaction occurs photolytically in the
skin, it may be that the higher vitamin D level in the
ODP in this study reflects increased occupational exposure. It should be noted that the study was conducted
in Queensland, Australia which has such a high incidence of skin malignancy that it is commonly referred
to as the ‘melanoma capital of the world’.54 Opioids
are well known to have various endocrine35 50 53 55–57
and immune potentiating actions35–38 49 51 58 which have
been addressed elsewhere and it is possible that indirect effects on vitamin D metabolism may be mediated
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806

through such pathways. Moreover, the relationship with
vitamin D status and the square of chronological age was
fascinating and suggests a positive feed forward process
as has been found for arterial stiffness in various drug
dependencies.7 59 60
Although both elevated levels of vitamin D on the
one hand (present report) and calcium and phosphate
and their solubility products on the other hand22 have
been noted in our patients in opioid dependency, as
no correlation was established between the two sets of
parameters, it is unlikely based on the present analysis that a direct relationship exists between them.
However, as the vitamin D-binding globulin (VDBG)
has not been measured in the present work, it may be
that this provides the computational and mechanistic
‘missing link’ between the two groups of data. Moreover as the vitamin D binding globulin (VDBG, Group
Specific Component Globulin, gc component, gc globulin) is generated in the liver61 62 and liver dysfunction
has been well described both in opioid dependency and
in HCV infection, this is an important issue for future
workers in this area. At the time of writing however,
we are not aware that such assays are available in this
country. Parallel analyses have found that this situation
is of particular relevance to the case of the circulating
levels of sex hormones and their binding globulin in
men and women in our cohort53 and it may well be the
case therefore in the case of vitamin D physiology. It
is important to underscore that the highly significant
results obtained in the present analysis for the patients
with hepatitis C seronegative opioid dependency imply
that hepatic dysfunction alone is not likely to account
for the observations reported herein. Biomarkers of
ageing have been reported to be derived from any variable which changes with age.39 Such biomarkers can
change in either a positive or negative direction with
age. Both ALT and globulins rise dramatically with
age and so have been described as positive age-related
9
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biomarkers.37 38 49 51 63 In the ODPs described in the
present study, vitamin D levels fell with age which would
make vitamin D a negative biomarker of age in the
drug-dependent cohort (tables 2–4, figures 1 and 3A,B
and see the online supplementary figure 1). Moreover,
10

vitamin D status was also shown to correlate with ALT in
drug dependence which is a well-established biomarker
of ageing.
Interestingly very high levels of osteoporosis/osteopaenia have been noted in ODP groups by several
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806

BMJ Open: first published as 10.1136/bmjopen-2017-016806 on 13 January 2018. Downloaded from http://bmjopen.bmj.com/ on 9 October 2018 by guest. Protected by copyright.

Figure 3 Logarithm vitamin D by hepatitis C serostatus by: (A) age and sex using linear lines of best fit; (B) age and sex using
loess (localised polynomial) curves of best fit and (C) over the first 3 years by sex.
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Parameter
Variable

Value

SE

df

Model
t Value

P value

AIC

BIC

logLik

1046.232

1077.646

−516.1161

1077.582

1131.343

−526.7911

2737.466

2776.991

−1361.733

2745.271

2796.080

−1363.636

1809.922

1851.731

−896.9608

984.101

1011.518

−486.0503

2641.788

2703.304

1862.039

1924.291

Case-control series
Linear model
 Status addicted

0.3814

0.1121

118

3.4025

0.0009

−0.0062

0.0026

118

−2.3991

0.0180

 Days

0.0001

0.0000

118

2.3023

0.0231

 Age: days

0.0000

0.0000

118

−2.2675

0.0252

0.1798

0.0497

113

3.6176

0.0004

−0.0017

0.0005

113

−3.1549

0.0021

0.0026

0.0009

113

2.8283

0.0055

 Days: status addicted

−0.0001

0.0000

113

−2.7344

0.0073

 Age: status addicted

−2.3528

0.8716

113

−2.6995

0.0080

 Age: days

−0.0009

0.0004

113

−2.5102

0.0135

0.0000

0.0000

113

2.1706

0.0321

 Age: status addicted

Quadratic model
 Status addicted
2

 (Age) : days: status addicted
 Age: days: status addicted

 Days
All patients
 Status addicted

0.4253

0.0588

514

7.2353

0.0000

 Age: status addicted

−0.0072

0.0015

514

−4.8060

0.0000

 Days: status addicted

−0.0003

0.0001

514

−4.7578

0.0000

0.0000

0.0000

514

3.7269

0.0002

 Age: days
All patients including sex
 Status addicted

0.3496

0.0637

512

5.4913

0.0000

−0.0072

0.0015

512

−4.7819

0.0000

 Age: days: status addicted

0.0000

0.0000

512

−4.4102

0.0000

 Sex male: status addicted

0.1127

0.0289

512

3.9009

0.0001

 Age: days

0.0000

0.0000

512

3.6454

0.0003

−0.0084

0.0018

317

−4.6726

0.0000

 Status addicted

0.4560

0.1124

317

4.0554

0.0001

 Days: status control

0.0002

0.0001

317

2.7606

0.0061

−0.0001

0.0001

317

−2.7125

0.0070

 Age: days: status addicted

0.0000

0.0000

193

−3.3598

0.0009

 Status addicted

0.1027

0.0381

193

2.6984

0.0076

 Age: days

0.0000

0.0000

193

2.5055

0.0131

0.1022

0.0191

442

5.3506

0.0000

−0.0018

0.0004

442

−4.4320

0.0000

0.0000

0.0000

442

−3.3350

0.0009

 Age: status addicted

Men
 Age: status addicted

 Days: status addicted
Women

All patients including biochemistry
 ALT: status addicted
 Age: ALT: status addicted
 Age: days: ALT: globulin: status
addicted
 Age: days: ALT: globulin: status control

0.0000

0.0000

442

2.8871

0.0041

−0.0107

0.0050

442

−2.1345

0.0334

0.1022

0.0209

281

4.8779

0.0000

 Age: ALT: status addicted

−0.0020

0.0005

281

−4.3398

0.0000

 Days: ALT: status addicted

−0.0001

0.0000

281

−3.9903

0.0001

0.0001

0.0000

281

2.8297

0.0050

 ALT: globulin: status control

−1309.894

Males with biochemistry
 ALT: status addicted

 Days: ALT

−919.0196

Continued
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Parameter
Variable

Value

Model

SE

df

t Value

P value

 Age: days: ALT: globulin

0.0000

0.0000

281

−2.3787

0.0180

 Days: ALT: globulin

0.0003

0.0001

281

2.3190

0.0211

 Age: days: globulin
 Days: globulin

0.0000

0.0000

281

2.3006

0.0221

−0.0010

0.0005

281

−2.2099

0.0279

AIC

BIC

logLik

Females with biochemistry
 Globulin: status addicted
 Age: globulin: status addicted
 Age: dd: ALT: globulin: status addicted

0.2158

0.0669

150

3.2246

0.0015

−0.0076

0.0024

150

−3.1375

0.0021

0.0000

0.0000

150

−2.9772

0.0034

−0.0394

0.0139

150

−2.8385

0.0052

 Age: ALT: globulin: status addicted

0.0016

0.0006

150

2.8339

0.0052

 Age: days: ALT

0.0000

0.0000

150

2.5096

0.0132

 Age: days

0.0000

0.0000

150

−2.3426

0.0205

 ALT: globulin

979.508

1037.669

−476.754

AIC, Akaike Information Criterion; ALT, alanine aminotransferase; BIC, Bayesian Information Crieterion; log Lik, Log Likelihood ratio.

authors.5 64–66 Clearly the higher levels of vitamin D seen
in this study are not in accordance with such a finding.
However, an inverse effect may be mediated by either a
higher level of VDBG or a block to the metabolism of
vitamin D to the active form 1,25-dihydroxycholecalciferol. Such a finding must await further studies. Moreover, the generally immunologically activated milieu of
opiate dependence is now increasingly well characterised.35 37 39 49 63 It may be that the immune active environment, with higher levels of interleukin-1, interleukin-6,
tumor necrosis factor-alpha and Monocyte Chemotactic
Protein 1/Chemokine (C-C motif) Ligand 2 (MCP-1/
CCL2) among other key cytokines,67 is the dominant
force acting on bone mineralisation and overwhelms
any relatively minor effect related to vitamin D metabolism. Interestingly melanocortin receptor-1 has been
identified in the skin.68 P53-induced photoactivation of
pro-opiomelanocortin synthesis has been shown to be
linked with cutaneous β-endorphin release, elevated pain
thresholds and naloxone-inducible withdrawal after sun
exposure. It is therefore potentially possible that ODPs
may be self-medicating the possibility of withdrawal by
elevating their rate of sun exposure.69 Further intriguing
conceptual possibilities emerge. Opioid dependence is
characterised by a subtle disruption of normal metabolism39 70 to the extent where patients have been compared
with prediabetics.50 56 71 72 Moreover, and in common with
many addictions, opioid dependence is characterised by
a marked immune stimulation36 37 39 58 73 and simulation
or at least phenocopying of the ageing process.6 7 9 39 45 74
It turns out that nuclear hormone receptors (NHRs) of
various classes facilely integrate such immunometabolic
signalling.75–80 NHRs of the oestrogen, androgen, pregnane, peroxisome proliferator activator receptor, liver
X receptor and rexinoids are involved along with the
vitamin D receptor.75 78 79 Importantly, there is significant heterodimerisation and apparent promiscuity
12

with many of these receptors81–83 including the vitamin
D receptor84–90 and involvement of these pathways in
diverse cell processes including stem cell regeneration,91–96 atherogenesis78 97–101 and cancer.83 102–106 As
altered metabolism, immunosenescence, cancerogenesis
and stem cell failure are all well described in the ageing
literature,28 29 107–109 it would appear that pathophysiologically, phenotypically and clinically important processes
may be impacted by the changes reported in the present
paper.
This study had various strengths and limitations.
The large sample size, prospective design, longitudinal
nature and real-world sampling for the groups were
major strengths. As the study was taken from ‘real-world
participants’ and as the opioid use has previously been
shown to be typical of that reported in many other clinical series, we feel that these results may be generalisable to opioid-dependent populations elsewhere. As
the drug use data were not available in these patients,
it was not possible to compare drug use levels with
vitamin D status or calculate dose–response relationships. Similarly, anthropometric including body mass
index data and sun exposure information is not available. The extent of vitamin D supplementation used
by patients is also unknown, but it is believed that its
use would be more widespread among controls than in
ODP, thereby acting in the reverse direction. Socioeconomic and occupational data were also not available to
the present study. While every attempt has been made
to adjust the findings for measured confounding variables, the involvement of unmeasured confounding
in the present results is not known. Nevertheless, the
robustness of the present findings to various data
manipulations including longitudinal and multivariate
adjustment suggests that the finding is genuine. These
findings could be supported by future mechanistic and
interventional studies. The unavailability of VDBG assay
Reece AS, Hulse GK. BMJ Open 2018;8:e016806. doi:10.1136/bmjopen-2017-016806
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